Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diet effect on gastrointestinal adverse events during pirfenidone treatment in idiopathic pulmonary fibrosis
2016-003827-45Phase 4Active
- Sponsor
- Instituto de Salud Carlos III
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Instituto de Salud Carlos III. Primary endpoint: Incidence of gastrointestinal adverse events. Started Nov 2017; status: active.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2016-003827-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003827-45.